** Shares of drug developer Keros Therapeutics fall 10.26% to $11.20 premarket
** Co says it has voluntarily halted all dosing in a mid-stage trial due to safety concerns
** Adds is terminating the trial early, and patients are expected to be monitored through the end-of-trial visits
** The mid-stage trial was studying its experimental drug cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, a rare lung condition that causes high blood pressure in the pulmonary arteries
** Earlier in Dec., co halted the 3.0 mg/kg and 4.5 mg/kg treatment based on the observation of pericardial effusions, build up of fluids around the heart, at those dose levels
** Co has notified investigators and certain regulatory authorities, including the FDA, about this decision, and is in the process of notifying other relevant regulatory authorities
** Stock fell ~60% last year
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.